ScripPfizer Inc. is to pay $810m to buy Swiss rare disease company Therachon AG , to obtain its asset TA-46 for achondroplasia, the most common form of short-limbed dwarfism. The deal terms mean that Pfi
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent M&A activity – licensing and alliances are cover